Mirum Pharmaceuticals (MIRM) Provides Development Program Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. LLY
5. TSLA
6. META
7. FICO
8. CART
9. INTC
10. SPCX

Go back to Mirum Pharmaceuticals (MIRM) Provides Development Program Updates

Mirum Pharmaceuticals Provides Development Program Updates

November 29, 2022 7:30 AM EST

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility. ICP is a setting of cholestasis during pregnancy with pruritus and elevated bile acid levels that can lead to fetal complications. In an interim analysis, patients treated with volixibat saw meaningful reductions in serum bile acids and pruritus. However, due to the challenges in enrollment in this high-risk pregnancy setting, Mirum has decided to discontinue OHANA, which allows the company to... More